Drug Trial Radar · NCT03182907
Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)
Last checked: Nov 20, 2026Latest source record: Jul 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
148
Actual
Start
Mar 27, 2018
Primary completion
May 12, 2022
Study completion May 12, 2022
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jun 9, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of this study are to evaluate the pharmacokinetics (PK), safety, and tolerability of bezlotoxumab (MK-6072) in children aged 1 to \<18 years of age with a confirmed diagnosis of Clostridium difficile infection (CDI) who are receiving antibacterial drug treatment. The primary hypothesis is that the area under the concentration-time curve from 0 to infinity (AUC0-inf) of bezlotoxumab after treatment of pediatric participants with bezlotoxumab is similar when compared to the AUC0-inf of bezlotoxumab after treatment of adults with bezlotoxumab.
Conditions
- Clostridium Difficile Infection
Interventions
BezlotoxumabBiological
A single intravenous (IV) infusion of 10 mg of bezlotoxumab per kg body weight. Dose may then be changed based on results from initial 12 participants.
PlaceboDrug
A single IV infusion of placebo for bezlotoxumab consisting of either 0.9% sodium chloride or 5% dextrose.
Antibacterial drug treatment (ABD)Drug
ABD will be administered for 10-21 days including the duration of ABD prior to the screening visit, during the screening period, and after the infusion of study treatment, per institutional guidelines, at the investigator's discretion. ABD is defined as the receipt of oral metronidazole, oral vancomycin, intravenous (IV) metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Concentration-Time Curve of Bezlotoxumab From Time 0 to Infinity (AUC0-inf)Time frame: Day 1 (2 hours postdose), Days 10, 29, 57, and 85
- Percentage of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 12 weeks
- Percentage of Participants Who Discontinued Study Due to an AETime frame: Up to approximately 12 weeks
Locations
75 sites in 17 countries. Site status is shown where the registry gives one.
Children's Hospital - Los Angeles ( Site 0021)
Los Angeles, California
UCSF Medical Center ( Site 0049)
San Francisco, California
Children's Hospital - Colorado ( Site 0013)
Aurora, Colorado
Children's Center for Digestive Healthcare ( Site 0052)
Atlanta, Georgia
University of Chicago ( Site 0019)
Chicago, Illinois
Our Lady of the Lake Hospital ( Site 0007)
Baton Rouge, Louisiana
The Johns Hopkins Rubenstein Child Health Building ( Site 0034)
Baltimore, Maryland
Tufts Medical Center-Floating Hospital for Children ( Site 0046)
Boston, Massachusetts
Mayo Clinic - Rochester ( Site 0004)
Rochester, Minnesota
Washington University ( Site 0037)
St Louis, Missouri
Columbia University Medical Center/ MSCHONY ( Site 0042)
New York, New York
SUNY Upstate Medical Center, University Hospital ( Site 0027)
Syracuse, New York
Montefiore Einstein Center ( Site 0041)
The Bronx, New York
Duke University Health System ( Site 0025)
Durham, North Carolina
Cincinnati Children's Hospital Medical Center ( Site 0024)
Cincinnati, Ohio
University Hospitals Cleveland Medical Center ( Site 0029)
Cleveland, Ohio
St. Jude Children's Research Hospital ( Site 0050)
Memphis, Tennessee
Vanderbilt University Medical Center ( Site 0022)
Nashville, Tennessee
The Children's Hospital of San Antonio ( Site 0009)
San Antonio, Texas
Primary Children's Hospital ( Site 0001)
Salt Lake City, Utah
Seattle Childrens Hospital ( Site 0028)
Seattle, Washington
Hospital Privado de Cordoba ( Site 2102)
Córdoba, Argentina
Hospital Italiano de Buenos Aires. ( Site 2103)
Caba, Buenos Aires, Argentina
Instituto de Oncologia Pediatrica - GRAACC - Unifesp ( Site 0205)
São Paulo, Brazil
Santa Casa de Misericordia de Belo Horizonte ( Site 0208)
Belo Horizonte, Minas Gerais, Brazil
Hospital de Clinicas da Universidade Federal do Parana ( Site 0203)
Curitiba, Paraná, Brazil
Hospital Pequeno Principe ( Site 0200)
Curitiba, Paraná, Brazil
Hospital Universitario da Universidade Federal de Santa Maria ( Site 0209)
Santa Maria, Rio Grande do Sul, Brazil
Hospital Pablo Tobon Uribe-Infectology pediatric ( Site 2166)
Medellín, Antioquia, Colombia
Fundacion Santa Fe de Bogota ( Site 2167)
Bogotá, Bogota D.C., Colombia
Fundacion Cardioinfantil Instituto de Cardiologia ( Site 2163)
Bogotá, Bogota D.C., Colombia
Fundacion Valle del Lili ( Site 2161)
Cali, Valle del Cauca Department, Colombia
Centro Medico Imbanaco ( Site 2160)
Cali, Valle del Cauca Department, Colombia
2. LF UK a FN Motol ( Site 2003)
Prague, Czechia
Fakultni Nemocnice Brno Bohunice ( Site 2000)
Brno, Brno-mesto, Czechia
Fakultni nemocnice Plzen ( Site 2001)
Plzen Lochotin, Plzeň Region, Czechia
Universitaetsklinikum Hamburg Eppendorf ( Site 1402)
Hamburg, Germany
Universitaetsklinikum Muenster ( Site 1400)
Münster, North Rhine-Westphalia, Germany
Semmelweis University-II.sz. Gyermekgyógyászati Klinika ( Site 2201)
Budapest, Hungary
Del-pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet ( Site 2202)
Budapest, Hungary
Showing 40 of 75 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.